Bristol-Myers Squibb Co. (BMY)
The Company, through its divisions and subsidiaries, is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of pharmaceuticals and other health care related products.
Recs
1firebird
(< 20)
Submitted: 8/26/2006 3:05:06 AM :
Start Price:
$18.89
BMY Score:
+44.23
change in CEO &/or ownership
Recs
30andholding
(91.75)
Submitted: 9/16/2009 2:27:46 PM :
Start Price:
$22.29
BMY Score:
+10.60
P/E is not overly high. There's a good dividend and they have enough cash on hand to completely cover their LT debt.
Recs
37weeks
(55.06)
Submitted: 4/27/2009 5:10:52 PM :
Start Price:
$19.86
BMY Score:
-3.29
Bristol Meyers Squib is positioned to take advantage of the push in the health industry by the increase of elderly people needing health care. This push bodes well for the Pharma sector in general.
Recs
549549
(89.19)
Submitted: 1/4/2007 11:57:53 AM :
Start Price:
$23.35
BMY Score:
+26.10
big farma a bit undervalued, look for it to outpace the S&P this year
Recs
acts412
(68.51)
Submitted: 10/10/2009 11:21:41 PM :
Start Price:
$22.59
BMY Score:
+9.47
positive independent ratings. best drug manufacturer. S&P 5 stars. 5.5% div. historically low PE of 13 x's trailing EPS.
Recs
Alex1963
(97.34)
Submitted: 1/7/2009 4:35:20 AM :
Start Price:
$21.31
BMY Score:
-2.97
(Put in at 21.57 5/07). P/E 23 at 22.35. Cap 46B 52 week $16-$27. Creaming the S&P since 10/08. Fairly steady growth from 3/06 at $22 until 7/07 at $31. Began downward trend 1/08 til it slid down then fell off cliff 10/08. Yield 5.3, Dividend 1.24, Payout .62. P/B 3.55, Good mgt & nargin #s. LT debt/E .46
MF AS 260/13 outperform. 4 star
Hold
Recs
alexreising
(94.38)
Submitted: 6/22/2009 6:04:11 PM :
Start Price:
$19.60
BMY Score:
+5.81
I may add this for some consumer healthcare exposure, will also happily accept dividend and will sell monthly covered calls. Between selling covered calls and dividend yield + some modest appreciation, this should be a 15% a year ROI.
Recs
alexxlea
(79.74)
Submitted: 10/14/2008 2:39:29 PM :
Start Price:
$17.37
BMY Score:
+30.73
People need this stuff.
Recs
alvesiii
(72.41)
Submitted: 4/10/2007 8:36:27 PM :
Start Price:
$24.39
BMY Score:
+23.87
It will be bought out
Recs
Analyst4Hire
(54.56)
Submitted: 5/29/2008 9:35:32 AM :
Start Price:
$20.24
BMY Score:
+43.78
No matter what the economy has in store, people get hurt, get sick, or get old. Bristol-Myers has been down for a while, look for their fortunes to change as investors search for downturn immune companies.
Recs
arabiafinesse
(< 20)
Submitted: 11/9/2008 2:51:20 AM :
Start Price:
$19.72
BMY Score:
+10.00
I am sorry ,but that remains confidential.I could be very wrong.
Recs
aracer
(99.65)
Submitted: 2/16/2009 11:03:49 AM :
Start Price:
$20.42
BMY Score:
-15.80
Strong pipeline. Good yield at a good entry.
Recs
awallejr
(81.52)
Submitted: 9/8/2008 2:28:20 AM :
Start Price:
$20.44
BMY Score:
+35.75
Excellent dividend, good pipeline.
Recs
babaker11
(< 20)
Submitted: 7/10/2008 10:31:34 PM :
Start Price:
$19.79
BMY Score:
+36.56
Hovering at it's 52 week low and bound for recovery. Get it while it's cheap!
Recs
balilight
(65.83)
Submitted: 10/29/2007 12:09:46 AM :
Start Price:
$26.64
BMY Score:
+20.48
Big pharma may not be sexy but the 3.5 Quarterly dividend yeild, good pavlix sales and seady performance is very attractive in these volital times.
Recs
banjojim
(47.83)
Submitted: 5/9/2009 4:36:17 PM :
Start Price:
$19.50
BMY Score:
+8.81
regular growing dividend. good for widows and orphans and old guys (like me)
Recs
bdz
(85.49)
Submitted: 6/8/2007 2:46:44 PM :
Start Price:
$25.55
BMY Score:
-22.11
Troubles with some meds, but OK in long run
Recs
ben1341
(< 20)
Submitted: 1/22/2007 12:03:44 AM :
Start Price:
$23.23
BMY Score:
+27.77
Merger or acquisition within two years.
Recs
BernieSr63
(< 20)
Submitted: 12/19/2008 9:42:36 PM :
Start Price:
$21.84
BMY Score:
-10.54
BMY has partnered with Exelixis and other pharmaceuticals with large pipelines and, with the agreements made will have a fair outlook in the oncology field.
With their Cash and free cash flow and their solid dividends, p/e ratio, EPS, their target given on Yahoo will be raised to at 25.50.
Recs
bif35624
(< 20)
Submitted: 2/11/2007 7:27:07 AM :
Start Price:
$23.61
BMY Score:
+26.53
New product pipeine ready to roll
RSS Headlines
Fool UK
- Show Me:
-
Outperform
-
Underperform
-
All
- Sort by:
-
Author
-
Recs
-
Date
-
Member Rating
-
Results 1 - 20 of 215 1 2 3 4 5 6 7 8 9 10 Next »